Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 21, 2026, 12:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2425–2448 of 2,796 matching trials from the live ClinicalTrials.gov search.
Conditions
Neurosciences, Substance-Related Disorders, Behavior Problem
Interventions
Placebo TMS Sham, Marinol 10Mg Capsule TMS Sham, Marinol 30Mg Capsule TMS Sham, Placebo TMS Real, Marinol 10Mg Capsule TMS Real, Marinol 30Mg Capsule TMS Real
Device · Drug · Other
Lead sponsor
Michael J. Wesley, PhD
Other
Eligibility
18 Years to 34 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Lexington, Kentucky
Recruiting Not applicable Interventional Accepts healthy volunteers

Combined Oral Motor Stimulation and Language on Preterm Infant Feeding

NCT05861531
Conditions
Language Delay, Language Development, Feeding; Difficult, Newborn, Mother-Infant Interaction, Maternal Behavior
Interventions
Oromotor stimulation, Reading curriculum, LENA recording, LENA linguistic feedback, No oromotor stimulation
Behavioral
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
23 Weeks to 30 Weeks
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Acute Ischemic Stroke
Interventions
tPA in combination with the Sonolysis Headframe (TUS), tPA in combination with the Sonolysis Headframe (Sham TUS)
Device
Lead sponsor
Cerevast Medical, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Memphis, Tennessee • Houston, Texas
Conditions
Hypertension, Left Ventricular Hypertrophy, Overweight
Interventions
Aliskiren 150/300 mg, Losartan 50/100 mg, Aliskiren placebo, Losartan 50/100 mg placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic
Interventions
Botensilimab, Balstilimab, Chloroquine Phosphate, Celecoxib, Nab paclitaxel, Gemcitabine, Cisplatin
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Scottsdale, Arizona
Conditions
Adult Solid Tumor
Interventions
SQZ-PBMC-HPV, Atezolizumab, Ipilimumab, Nivolumab
Biological · Drug
Lead sponsor
SQZ Biotechnologies
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 7 more
Conditions
Opioid Use Disorder
Interventions
Ketamine, Mindfulness-Oriented Recovery Enhancement (MORE), Support Group
Drug · Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
La Jolla, California • Salt Lake City, Utah
Conditions
Advanced Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
Interventions
Bright White Light Therapy, Combination Drug Therapy, Electronic Health Record Review, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
60 Years and older · Male only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Duarte, California
Conditions
Vertigo, Dizziness, Benign Paroxysmal Positional Vertigo, Labyrinthitis
Interventions
Osteopathic Manipulative Treatment (OMT), Vestibular Rehabilitation Therapy (VRT)
Other
Lead sponsor
Western University of Health Sciences
Other
Eligibility
18 Years to 79 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Pomona, California
Conditions
Retinoblastoma, Clear Cell Sarcoma, Renal Cell Carcinoma, Rhabdoid Tumor, Wilms Tumor, Hepatoblastoma, Neuroblastoma, Germ Cell Tumors, Ewings Sarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma, Osteosarcoma, Rhabdomyosarcoma
Interventions
Simvastatin, Cyclophosphamide, Topotecan, Myeloid growth factor
Drug
Lead sponsor
Emory University
Other
Eligibility
1 Year to 29 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Meningitis, Meningococcal Meningitis, Meningococcal Infections
Interventions
Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine, Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed, GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
10 Years to 17 Years
Enrollment
1,715 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
35
States / cities
Birmingham, Alabama • Huntsville, Alabama • Downey, California + 28 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Weight Loss and Exercise for Communities With Arthritis in North Carolina

NCT02577549
Conditions
Osteoarthritis
Interventions
Diet & Exercise, Attention Control
Behavioral
Lead sponsor
Wake Forest University
Other
Eligibility
50 Years and older
Enrollment
823 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Waynesville, North Carolina • Winston-Salem, North Carolina
Conditions
Human Immunodeficiency Virus
Interventions
3BNC117, 10-1074, Analytical treatment interruption
Drug · Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Conditions
Perfectionism, Intolerance to Uncertainty
Interventions
Cognitive Bias Modification, Cognitive Bias Modification for Control Group
Behavioral
Lead sponsor
Istanbul Sabahattin Zaim University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Lowell, Massachusetts
Conditions
Hypertension
Interventions
amlodipine and olmesartan medoxomil tablets, hydrochlorothiazide tablets
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
72
States / cities
Birmingham, Alabama • Green Valley, Arizona • Mesa, Arizona + 69 more
Completed No phase listed Observational Results available

ClotTriever Outcomes (CLOUT) Registry

NCT03575364
Conditions
Deep Vein Thrombosis Leg, DVT, Chronic DVT of Lower Extremity, Acute DVT of Lower Extremity
Interventions
ClotTriever
Device
Lead sponsor
Inari Medical
Industry
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
43
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 37 more
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Lazertinib, Amivantamab, Carboplatin, Pemetrexed
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
18
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 12 more
Conditions
Leukemia
Interventions
filgrastim, asparaginase, cyclophosphamide, daunorubicin hydrochloride, dexamethasone, etoposide, leucovorin calcium, liposomal cytarabine, mercaptopurine, mesna, methotrexate, therapeutic hydrocortisone, thiotepa, vincristine sulfate, low-LET electron therapy, low-LET photon therapy
Biological · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 20 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
62
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 48 more
Conditions
Type 2 Diabetes (Adult Onset)
Interventions
Tirzepatide, Pioglitazone, Sitagliptin, Metformin HCI XR
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 75 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
San Antonio, Texas
Conditions
System; Lupus Erythematosus
Interventions
Mymee Program
Behavioral
Lead sponsor
Mymee Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Completed Not applicable Interventional Accepts healthy volunteers Results available

Ultherapy™ Treatment Following Sculptra® Treatment

NCT01422538
Conditions
Skin Laxity
Interventions
Ulthera® System, Sculptra®, Sculptra® treatment followed by Ultherapy™ treatment
Device · Drug · Other
Lead sponsor
Ulthera, Inc
Industry
Eligibility
35 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Obstructive Sleep Apnea, Cognitive Decline
Interventions
Positive airway pressure, Oral appliance therapy, Positional therapy
Device
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
55 Years to 85 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
Tucson, Arizona • New York, New York • Pittsburgh, Pennsylvania
Conditions
Acute Renal Failure (ARF), Acute Tubular Necrosis
Interventions
QRX-3
Drug
Lead sponsor
Ebima Clifford Okundaye
Industry
Eligibility
10 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rosharon, Texas
Conditions
Non-small Cell Lung Cancer
Interventions
Exercise
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Houston, Texas